KIMBERLY MORIN: Open Payments
NPI 1558790105 · ARNOLD, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$530 in 24 payments from 13 companies in 2025. Trend: 2023 $322 · 2024 $398 · 2025 $530
Food & beverage: $530
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $218 |
| Boston Scientific Corporation | 1 | $45 |
| Lilly USA, LLC | 2 | $38 |
| Abbott Laboratories | 2 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $26 |
| Exact Sciences Corporation | 1 | $25 |
| ABBVIE INC. | 1 | $21 |
| Optinose US, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $17 |
Products named: Rybelsus, Wegovy, Ozempic, WaveWriter Alpha Prime 16, MOUNJARO, FREESTYLE LIBRE 3, XIFAXAN, CAPLYTA.
Industry payments across MD — which companies pay providers there.
